1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Simris Alg AB (publ)

Simris Alg AB (publ)

SIMRIS-B.ST
Simris Alg AB (publ)SE flagStockholm Stock Exchange
0.09
SEK
+0.00
- -
46.40MMarket Cap
Simris Alg AB (publ)
SIMRIS-B.ST
(Stockholm Stock Exchange)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.02
0.04
0.04
0.03
0.05
0.02
0.07
0.03
0.02
0.01
- -
- -
Revenue per Share
-0.4
-0.79
-1
-1.09
-0.93
-0.82
-0.22
-0.35
-0.17
-0.16
-0.1
-0.04
-0.04
Basic EPS, GAAP
-0.49
-2.15
-1.76
-1.13
-0.87
-0.54
-0.17
-0.22
-0.28
-0.17
-0.05
-0.03
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.71
-1.76
1.02
2.02
0.74
-0.22
0.06
0.08
0.11
0.13
0.02
0.02
- -
Book Value per Share
0.31
2.4
3.22
1.9
1.46
0.99
0.38
0.22
-0.93
-0.52
-0.38
-0.19
-0.15
Tangible Book Value per Share
21
15
19
21
26
33
119
82
142
229
348
630
758
Basic Weighted Avg Shares
- -
- -
1
1
1
2
2
6
4
4
3
2
2
Sales/Revenue/Turnover
-15,436.36
-4,086.18
-2,582.82
-2,654.78
-2,975.2
-1,412.85
-1,093.91
-471.37
-604.34
-841.41
-1,201.18
-1,830.46
-1,484.04
Operating Margin (%)
- -
1
2
3
3
3
3
6
7
14
15
14
14
Depreciation Expense
-8
-12
-19
-23
-24
-27
-26
-28
-24
-37
-35
-27
-27
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-15,365.45
-4,167.51
-2,664.2
-2,698.05
-3,145.8
-1,544
-1,182.09
-462.05
-598.58
-856.8
-1,197.4
-1,660.12
-1,436.33
Profit Margin (%)
6
24
31
11
10
7
21
-3
-16
-5
-13
-9
- -
Working Capital
- -
7
6
6
4
3
3
2
2
1
1
1
- -
LT Debt
10
39
65
43
40
35
47
18
23
26
6
- -
5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-73.53
-77.65
- -
- -
-415.56
-217.2
-162.54
-189.66
-308.74
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
1
- -
LT Borrowings
- -
1
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
625
842
1,350
Market Capitalization
62
25
76

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
5
16
12
Cash, Cash Equivalents & STI
4
1
11
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
1
1
Total Current Liabilities
29
25
13
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-15.94%
-42.06%
-108.33%
Free Cash Flow
0.37%
8.72%
-12.67%
Net Income, GAAP
11.42%
3.97%
-22.52%
Sales/Revenue/Turnover
39.49%
15.76%
-44.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
3
2025
- -
1
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.03
-0.02
-0.03
-0.1
2025
-0.01
-0.01
-0.01
-0.01
-0.04
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Acepodia, Inc. (6976.TWO)
HAVN Life Sciences Inc. (HAVN.CN)
LigaChem Biosciences Inc. (141080.KQ)
Cognition Therapeutics, Inc. (CGTX)
Addex Therapeutics Ltd (ADXN)
MacroGenics, Inc. (MGNX)
Business
Simris Group AB (publ), established in 2010 and headquartered in Hammenhög, Sweden, operates as a biotechnology company focused on harnessing the potential of microalgae and cyanobacteria. The company identifies and extracts high-value, natural, biologically active compounds for diverse applications. Its core activities span the biopharmaceutical sector, notably developing proprietary Antibody Drug Conjugate (ADC) payloads for cancer treatments, alongside active ingredients for skincare and sustainable nutrition products. Simris Group cultivates these microorganisms in advanced photobioreactor facilities, optimizing production of specialized compounds. The company continues to offer plant-based marine Omega-3 EPA and DHA supplements, providing alternatives to conventional sources, and engages in B2B biomass sales.